Skin Cancer Network Group Audit of Clinical Performance Indicators: Data quality and treatment quality Anna Murray BSc Cancer Information Analyst Anna.Murray@mccn.nhs.uk Standards for Better Health • Clinical performance indicators • Measurable and comparative data • Progress assessment locally and at network level • Merseyside and Cheshire CNG: Access to services Consistency of service provision Compliance with national targets Clinical Performance Indicators I. The number of newly diagnosed patients referred by trust and ICD-10 code: i. 31 day first definitive treatment ii. 62 day standard II. Performance of radiotherapy: i. Number of patients being treated ii. Waiting times for treatment Clinical Performance Indicators III. Clinical trial activity i. Accrual by MDT in to clinical trials IV. Sentinel lymph node biopsy i. Number of patients referred by Breslow score ii. Number of procedures performed V. Primary care excisions i. Number of primary care excisions taking place I. The number of newly diagnosed patients referred by trust and ICD-10 code: 2500 Treated after 31 days Treated on or within 31 days 1 Total treated 2000 Number of patients 1139 1 1500 772 1000 0 500 1140 367 773 367 0 C43 - Malignant melanoma of the skin C44 - Other malignant neoplasms of the skin (except basal cell carcinoma) Combined 31 day first definitive treatment: Total number of patients by tumour type for Merseyside and Cheshire (January to December 2008) I. The number of newly diagnosed patients referred by trust and ICD-10 code: 1200 Treated after 62 days Number of patients 1000 2 Treated on or within 62 days Total treated 542 800 600 2 0 400 287 255 544 200 255 289 0 C43 - Malignant melanoma of the skin C44 - Other malignant neoplasms of the skin (except basal cell carcinoma) Combined 62 day standard: Total number of patients by tumour type for Merseyside and Cheshire (January to December 2008) Data discrepancies • • • • • • Apparent between CWT data and local trust data Suggests issues across the network for data uploads Are performance figures inaccurate? Somerset Cancer Register should address this Must make sure that trusts are uploading all of their data Good quality data is the key Cancer waiting times data Local trust data Southport and Ormskirk 43 30 Warrington & Halton 12 15 Arrowe park 57 52 St Helens and Knowsley 40 93 Aintree 6 Awaiting data Countess of Chester 70 Awaiting data RLBUHT 91 90 Total 319 298 Trust Comparison of total numbers of patients first seen for Malignant Melanoma in Merseyside and Cheshire Cancer network by trust (January to December 2008) V. Primary care excisions Research and audit: ‘…the planned treatment of low-risk BCCs should be restricted to approved doctors…, usually a GPwSI…or the LSMDT/SSMDT. All other skin cancers should be referred to the LSMDT in the first instance (National Institute for Clinical Excellence, 2006).’ •If the lesion is not a BCC, then the patient should be urgently referred (National Institute for Health and Clinical Excellence, 2006) Abnormal growths/inflammations to be treated by GPs unless there is doubt with regards to diagnosis (National Institute for Health and Clinical • Excellence, 2006) V. Primary care excisions C43 - Malignant melanoma of the skin C44 - Other malignant neoplasms of the skin (except basal cell carcinoma) Combined RLBUHT 9 23 32 WUTH 2 20 22 St. Helens & Knowsley 6 13 19 Southport & Ormskirk Awaiting data Awaiting data Awaiting data Countess of Chester Awaiting data Awaiting data Awaiting data 17 56 73 Trust Network • Malignant melanoma – 4.6% • Squamous cell carcinoma – 7.2% • Combined – 6.4% V. Primary care excisions Findings: • Not all patients diagnosed with either malignant melanoma or squamous cell carcinoma are urgently referred via 2 week wait • What are the reasons for this? • Can such cases be avoided in the future? • Poorer patient experience? What next? • • • • • Clinical Performance Indicators Audit of excision completeness in primary care Monitoring uptake in to clinical trials Audit of patients referred for SLNB Breach analysis in CWT data